JP2011500024A - Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物 - Google Patents

Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物 Download PDF

Info

Publication number
JP2011500024A
JP2011500024A JP2010528899A JP2010528899A JP2011500024A JP 2011500024 A JP2011500024 A JP 2011500024A JP 2010528899 A JP2010528899 A JP 2010528899A JP 2010528899 A JP2010528899 A JP 2010528899A JP 2011500024 A JP2011500024 A JP 2011500024A
Authority
JP
Japan
Prior art keywords
cells
rpe cells
rpe
formulation
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010528899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500024A5 (cg-RX-API-DMAC7.html
Inventor
クリストファー マルクイト，
リンダ レミウクス，
ウィリアム ホルメス，
ペドロ ウェルタス，
ルーシー ビルナー，
Original Assignee
アドバンスド セル テクノロジー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドバンスド セル テクノロジー， インコーポレイテッド filed Critical アドバンスド セル テクノロジー， インコーポレイテッド
Publication of JP2011500024A publication Critical patent/JP2011500024A/ja
Publication of JP2011500024A5 publication Critical patent/JP2011500024A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C12N2501/734—Proteases (EC 3.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010528899A 2007-10-12 2008-10-10 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物 Withdrawn JP2011500024A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99866807P 2007-10-12 2007-10-12
US99876607P 2007-10-12 2007-10-12
US990808P 2008-01-02 2008-01-02
US991108P 2008-01-02 2008-01-02
PCT/US2008/011669 WO2009051671A1 (en) 2007-10-12 2008-10-10 Improved methods of producing rpe cells and compositions of rpe cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014125977A Division JP6137626B2 (ja) 2007-10-12 2014-06-19 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物

Publications (2)

Publication Number Publication Date
JP2011500024A true JP2011500024A (ja) 2011-01-06
JP2011500024A5 JP2011500024A5 (cg-RX-API-DMAC7.html) 2012-11-15

Family

ID=40567677

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2010528899A Withdrawn JP2011500024A (ja) 2007-10-12 2008-10-10 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2014125977A Active JP6137626B2 (ja) 2007-10-12 2014-06-19 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2017083243A Active JP6692768B2 (ja) 2007-10-12 2017-04-19 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2020072683A Pending JP2020115882A (ja) 2007-10-12 2020-04-15 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2022035111A Pending JP2022079484A (ja) 2007-10-12 2022-03-08 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2024205622A Pending JP2025036424A (ja) 2007-10-12 2024-11-26 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014125977A Active JP6137626B2 (ja) 2007-10-12 2014-06-19 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2017083243A Active JP6692768B2 (ja) 2007-10-12 2017-04-19 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2020072683A Pending JP2020115882A (ja) 2007-10-12 2020-04-15 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2022035111A Pending JP2022079484A (ja) 2007-10-12 2022-03-08 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2024205622A Pending JP2025036424A (ja) 2007-10-12 2024-11-26 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物

Country Status (13)

Country Link
US (4) US20110274662A1 (cg-RX-API-DMAC7.html)
EP (2) EP3636748A1 (cg-RX-API-DMAC7.html)
JP (6) JP2011500024A (cg-RX-API-DMAC7.html)
KR (2) KR101849336B1 (cg-RX-API-DMAC7.html)
CN (2) CN101878295A (cg-RX-API-DMAC7.html)
AU (1) AU2008312007A1 (cg-RX-API-DMAC7.html)
CA (3) CA3177952A1 (cg-RX-API-DMAC7.html)
DK (1) DK2209888T3 (cg-RX-API-DMAC7.html)
ES (1) ES2764473T3 (cg-RX-API-DMAC7.html)
IL (4) IL292561A (cg-RX-API-DMAC7.html)
PL (1) PL2209888T3 (cg-RX-API-DMAC7.html)
PT (1) PT2209888T (cg-RX-API-DMAC7.html)
WO (1) WO2009051671A1 (cg-RX-API-DMAC7.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013128476A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 眼杯様構造体の製造方法
JP2013128475A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜組織の製造方法
JP2013128474A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜色素上皮細胞の製造方法
JP2013128477A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜層特異的神経細胞を製造する方法
WO2018003908A1 (ja) * 2016-06-30 2018-01-04 株式会社ヘリオス 移植用媒体
JP2018500906A (ja) * 2014-12-18 2018-01-18 ユニヴェルシテ・ピエール・エ・マリ・キュリ・（パリ・６） 網膜変性処置のためのｏｔｘ２過剰発現トランスジェニック網膜色素上皮細胞
JP2018523682A (ja) * 2015-08-18 2018-08-23 アステラス インスティテュート フォー リジェネレイティブ メディシン 臨床製剤

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
SG10201912182UA (en) 2004-01-23 2020-02-27 Astellas Inst For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
JP5441099B2 (ja) 2007-01-18 2014-03-12 独立行政法人理化学研究所 視細胞への分化誘導方法
CA3177952A1 (en) 2007-10-12 2009-04-23 Astellas Institute For Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
CA2721952C (en) * 2008-04-22 2019-11-12 Regenerative Research Foundation Retinal pigment epithelial stem cells
JPWO2009148170A1 (ja) 2008-06-06 2011-11-04 独立行政法人理化学研究所 幹細胞の培養方法
ES2509567T3 (es) * 2009-08-28 2014-10-17 Cellular Dynamics International, Inc. Identificación de variación genética en tejidos afectados
DK2496688T3 (en) 2009-11-05 2017-04-03 Riken Method of Inducing Differentiation in Cultured Stem Cells
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
EP4524568A3 (en) 2010-07-23 2025-06-18 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
FI20106354A0 (fi) * 2010-12-20 2010-12-20 Suomen Punainen Risti Veripalvelu Menetelmä ihmisen retinan pigmentti-epiteelisolujen valmistamiseksi
KR101972610B1 (ko) 2011-05-18 2019-04-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 망막 질환을 치료하기 위한 조성물 및 방법
HUE044778T2 (hu) 2011-11-14 2019-11-28 Astellas Inst For Regenerative Medicine Humán RPE sejt gyógyászati készítmények és alkalmazásaik
JP6012164B2 (ja) 2011-11-25 2016-10-25 住友化学株式会社 多能性幹細胞由来の組織の凍結保存方法
CA2856867C (en) * 2011-11-25 2021-06-01 Sumitomo Chemical Company, Limited Methods for producing retinal tissue and retina-related cell
CN104136034B (zh) 2011-11-30 2018-04-24 安斯泰来再生医药协会 间充质基质细胞及其相关用途
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
US10519422B2 (en) * 2012-02-29 2019-12-31 Riken Method of producing human retinal pigment epithelial cells
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
WO2014100779A1 (en) 2012-12-21 2014-06-26 Advanced Cell Technology, Inc. Methods ofr production of platelets from pluripotent stem cells and compositions thereof
AU2014212230B2 (en) 2013-02-01 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for generating retinal pigment epithelium (RPE) cells from induced pluripotent stem cells (iPSCs)
AU2014246962A1 (en) * 2013-04-03 2015-11-19 Tampereen Yliopisto Methods and media for differentiating eye cells
EP3656853B1 (en) 2013-08-23 2023-02-15 Sumitomo Chemical Company, Limited Method for producing retinal tissue and retina-related cells
WO2015087231A1 (en) 2013-12-11 2015-06-18 Pfizer Limited Method for producing retinal pigment epithelial cells
AU2015336453B2 (en) 2014-10-24 2021-05-20 Riken Production method for nerve tissue
EP3211071B1 (en) 2014-10-24 2021-05-05 Sumitomo Dainippon Pharma Co., Ltd. Production method for retinal tissue
IL273405B2 (en) 2014-12-30 2024-01-01 Cell Cure Neurosciences Ltd Rpe cell populations and methods of generating same
CA2972700A1 (en) * 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Methods of treating retinal diseases
IL303401A (en) 2015-03-23 2023-08-01 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
CN108291206B (zh) 2015-09-08 2022-07-08 富士胶片细胞动力公司 干细胞来源的视网膜色素上皮的基于macs的纯化
ES2971677T3 (es) 2015-09-08 2024-06-06 Sumitomo Pharma Co Ltd Método para la producción de tejido retiniano
AU2016321170B2 (en) 2015-09-08 2022-09-01 Fujifilm Cellular Dynamics Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells
CN108350429B (zh) 2015-10-20 2022-02-25 富士胶片细胞动力公司 用于将多能干细胞定向分化为免疫细胞的方法
US12188047B2 (en) * 2015-10-26 2025-01-07 Hadasit Medical Research Services And Development Ltd. Preparation of retinal pigment epithelium cells
CN109312306B (zh) 2016-04-22 2023-05-09 住友制药株式会社 产生视网膜组织的方法
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
KR102668891B1 (ko) 2017-04-18 2024-05-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 항원-특이적 면역 이펙터 세포
WO2019054514A1 (ja) 2017-09-14 2019-03-21 国立研究開発法人理化学研究所 網膜組織の製造方法
CN107760649B (zh) * 2017-11-02 2021-03-30 北京全式金生物技术有限公司 一种用于人神经系统细胞培养和人多能性干细胞向神经系统细胞分化的营养添加剂
KR102198942B1 (ko) * 2019-07-02 2021-01-05 의료법인 성광의료재단 Pedf를 발현하거나 모세포에 비하여 pedf를 과발현하도록 유전적으로 조작된 중간엽 줄기세포
EP4001425A4 (en) * 2019-07-19 2023-04-19 Tokyo Electron Limited METHOD FOR ASSESSING THE STATE OF CELL DIFFERENTIATION
IL292610A (en) 2019-10-30 2022-07-01 Astellas Inst For Regenerative Medicine Methods for producing retinal pigment epithelium cells
JPWO2022191216A1 (cg-RX-API-DMAC7.html) 2021-03-09 2022-09-15
CA3254454A1 (en) 2022-03-16 2025-03-04 Racthera Co., Ltd. METHOD OF TRANSPLANTATION
CN119384700A (zh) 2022-04-15 2025-01-28 艾斯本神经科学公司 细胞分化状态的分类方法和分化细胞的相关组合物
EP4659755A1 (en) 2023-02-14 2025-12-10 RACTHERA Co., Ltd. Therapeutic drug for retinal pigment epithelium tears
CN119020271B (zh) * 2024-07-17 2025-06-06 中国农业大学 一种提高卵子体外成熟质量及体外受精后胚胎妊娠率的组合物、方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508302A (ja) * 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610753A (en) 1991-12-12 1997-03-11 Eastman Kodak Company Optical design of laser scanner to reduce thermal sensitivity
ATE196923T1 (de) 1993-04-30 2000-10-15 Photogenesis Inc Transplantation des retinalen pigmentepithels
DE19609838A1 (de) 1996-03-13 1997-09-18 Boehringer Mannheim Gmbh Verfahren und Teststreifen zur Bestimmung eines Analyten
US6878544B2 (en) 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US20040086494A1 (en) 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
WO1999012572A1 (en) 1997-09-10 1999-03-18 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
EP1044024A1 (en) 1998-01-02 2000-10-18 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
EP1066368A4 (en) 1998-03-02 2002-08-21 Compucyte Corp SELECTIVE CELL ANALYSIS
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
NZ518365A (en) 1999-10-28 2004-04-30 Univ Massachusetts Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
JP2003533976A (ja) 2000-01-07 2003-11-18 オレゴン ヘルス アンド サイエンス ユニバーシティ 胚分割による霊長類子孫のクローン性増殖
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
AU2001284160A1 (en) 2000-08-19 2002-03-04 Axordia Limited Modulation of stem cell differentiation
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
JP2004514702A (ja) 2000-11-29 2004-05-20 オキュレックス　ファーマシューティカルズ，　インコーポレイテッド 眼における移植拒絶を予防するための眼内インプラント
DE10108412B4 (de) 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
JP2004531262A (ja) 2001-05-15 2004-10-14 ラッパポート ファミリー インスチチュート フォア リサーチ イン ザ メディカル サイエンシズ ヒト胚性幹細胞由来インスリン産生細胞
KR101073411B1 (ko) 2001-07-12 2011-10-17 제론 코포레이션 인간 다분화능 줄기 세포로부터 제조된 심근 세포 계통의 세포
MXPA04005010A (es) 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
CN1602351B (zh) 2001-12-07 2011-03-30 杰龙公司 源自人胚胎干细胞的胰岛细胞
JP2005519881A (ja) 2001-12-11 2005-07-07 ファイブローゲン、インコーポレーテッド 眼プロセスの抑制方法
AU2003235652A1 (en) 2002-01-15 2003-07-30 Advanced Cell Technology, Inc. Cloning b and t lymphocytes
CA2482903A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US20040091936A1 (en) 2002-05-24 2004-05-13 Michael West Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
US7422736B2 (en) * 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
AU2003279132A1 (en) 2002-10-04 2004-05-04 Tissuetech, Inc. Retinal pigment epithelial cell cultures on amniotic membrane and transplantation
AU2003302020B2 (en) 2002-11-14 2008-01-31 Ethicon Endo-Surgery, Inc. Methods and devices for detecting tissue cells
US20040156878A1 (en) 2003-02-11 2004-08-12 Alireza Rezania Implantable medical device seeded with mammalian cells and methods of treatment
CN101044404A (zh) 2003-03-03 2007-09-26 长冈实业株式会社 用于不同类型细胞检测和定量的方法和装置以及生物光盘在该检测和定量中的应用
JP2006525006A (ja) 2003-05-08 2006-11-09 セルアーティス アーベー 閉塞ストローガラス化方法を利用するヒト胚盤胞由来幹細胞の低温保存法
KR100569168B1 (ko) 2003-08-08 2006-04-07 (주)아비코아생명공학연구소 조류 정원줄기세포의 배양방법 및 이에 의해 수득한 조류정원줄기세포
SG10201912182UA (en) 2004-01-23 2020-02-27 Astellas Inst For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
AU2005243158B2 (en) 2004-05-07 2010-03-25 Wisconsin Alumni Research Foundation Method of forming mesenchymal stem cells from embryonic stem cells
US6945971B1 (en) 2004-07-19 2005-09-20 Gwon Arlene E Controlled ocular lens regeneration
WO2006040763A2 (en) 2004-10-12 2006-04-20 Technion Research & Development Foundation Ltd. Isolated primate embryonic cells and methods of generating and using same
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
EP2048227B1 (en) 2005-02-11 2015-08-19 Agency For Science, Technology And Research Methods for proliferating stem cells
WO2007020655A1 (en) 2005-05-17 2007-02-22 Reliance Life Sciences Pvt Ltd Establishment of a human embryonic stem cell line using mammalian cells
US20080213233A1 (en) 2005-05-27 2008-09-04 Shu Wang Method of Delivering Nucleic Acid Molecules Into Embryonic Stem Cells Using Baculoviral Vectors
US8198085B2 (en) 2005-08-03 2012-06-12 Core Dynamics Limited Somatic cells for use in cell therapy
JP4926615B2 (ja) 2006-08-29 2012-05-09 太陽化学株式会社 ガラクトマンナン酵素分解物の製造方法
KR100832592B1 (ko) 2006-08-17 2008-05-27 박현숙 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법
ZA200901914B (en) 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
JP5395058B2 (ja) * 2007-04-18 2014-01-22 ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド 幹細胞に由来する網膜色素上皮細胞
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
CA3177952A1 (en) 2007-10-12 2009-04-23 Astellas Institute For Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
HU0700675D0 (en) 2007-10-15 2007-12-28 Mta Tamogatott Kutatohelyek Ir Method for monitoring stem cell differentiation
US20090226955A1 (en) 2007-12-21 2009-09-10 University Of Miami Immortalized retinal pigmented epithelial cells
US20090233324A1 (en) 2008-03-11 2009-09-17 Kopf-Sill Anne R Methods for Diagnosing Cancer Using Samples Collected From A Central Vein Location or an Arterial Location
CA2721952C (en) * 2008-04-22 2019-11-12 Regenerative Research Foundation Retinal pigment epithelial stem cells
US8652123B2 (en) 2008-09-02 2014-02-18 Geoffrey C. GURTNER Methods and devices for improving the appearance of tissue
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
EP4524568A3 (en) 2010-07-23 2025-06-18 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
WO2012149484A2 (en) 2011-04-29 2012-11-01 University Of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
HUE044778T2 (hu) 2011-11-14 2019-11-28 Astellas Inst For Regenerative Medicine Humán RPE sejt gyógyászati készítmények és alkalmazásaik
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
ES2688019T3 (es) 2012-06-05 2018-10-30 The Regents Of The University Of California Métodos y composiciones para la producción acelerada de células epiteliales pigmentadas retinianas a partir de células pluripotentes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508302A (ja) * 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013032930; Ｍｅｔｈｏｄｓ　Ｅｎｚｙｍｏｌ．，Ｖｏｌ．４１８（２００６）ｐ．１６９-１９４ *
JPN6013032931; Ｃｌｏｎｉｎｇ　ａｎｄ　Ｓｔｅｍ　Ｃｅｌｌｓ，Ｖｏｌ．８，Ｎｏ．３（２００６）ｐ．１８９-１９９ *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013128475A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜組織の製造方法
JP2013128474A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜色素上皮細胞の製造方法
JP2013128477A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜層特異的神経細胞を製造する方法
JP2013128476A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 眼杯様構造体の製造方法
US11865189B2 (en) 2014-12-18 2024-01-09 Sorbonne Universite Transgenic RPE cells overexpressing OTX2 for the treatment of retinal degeneration
JP2018500906A (ja) * 2014-12-18 2018-01-18 ユニヴェルシテ・ピエール・エ・マリ・キュリ・（パリ・６） 網膜変性処置のためのｏｔｘ２過剰発現トランスジェニック網膜色素上皮細胞
JP2018523682A (ja) * 2015-08-18 2018-08-23 アステラス インスティテュート フォー リジェネレイティブ メディシン 臨床製剤
US12419958B2 (en) 2015-08-18 2025-09-23 Astellas Institute For Regenerative Medicine Clinical formulations
US11013808B2 (en) 2015-08-18 2021-05-25 Astellas Institute For Regenerative Medicine Clinical formulations
JP2022040140A (ja) * 2015-08-18 2022-03-10 アステラス インスティテュート フォー リジェネレイティブ メディシン 臨床製剤
JP7043392B2 (ja) 2015-08-18 2022-03-29 アステラス インスティテュート フォー リジェネレイティブ メディシン 臨床製剤
US11957754B2 (en) 2015-08-18 2024-04-16 Astellas Institute For Regenerative Medicine Clinical formulations
JP7449915B2 (ja) 2015-08-18 2024-03-14 アステラス インスティテュート フォー リジェネレイティブ メディシン 臨床製剤
WO2018003908A1 (ja) * 2016-06-30 2018-01-04 株式会社ヘリオス 移植用媒体
US11524035B2 (en) 2016-06-30 2022-12-13 Healios K.K. Transplantation medium
JP7067744B2 (ja) 2016-06-30 2022-05-16 株式会社ヘリオス 移植用媒体
JPWO2018003908A1 (ja) * 2016-06-30 2019-07-11 株式会社ヘリオス 移植用媒体

Also Published As

Publication number Publication date
KR20160045933A (ko) 2016-04-27
IL204956A (en) 2016-06-30
US20220049217A1 (en) 2022-02-17
KR20100065373A (ko) 2010-06-16
KR101849329B1 (ko) 2018-04-16
WO2009051671A1 (en) 2009-04-23
AU2008312007A1 (en) 2009-04-23
IL204956A0 (en) 2010-11-30
US20110274662A1 (en) 2011-11-10
KR101849336B1 (ko) 2018-04-16
ES2764473T3 (es) 2020-06-03
CA2702386C (en) 2018-07-24
EP3636748A1 (en) 2020-04-15
CA2702386A1 (en) 2009-04-23
IL246181A0 (en) 2016-07-31
JP2025036424A (ja) 2025-03-14
IL324350A (en) 2025-12-01
US20150086512A1 (en) 2015-03-26
EP2209888B1 (en) 2019-12-04
DK2209888T3 (da) 2020-01-20
US10077424B2 (en) 2018-09-18
JP6692768B2 (ja) 2020-05-13
PL2209888T3 (pl) 2020-05-18
EP2209888A4 (en) 2011-02-09
CA3006687A1 (en) 2009-04-23
EP2209888A1 (en) 2010-07-28
CN101878295A (zh) 2010-11-03
US20190062703A1 (en) 2019-02-28
JP2020115882A (ja) 2020-08-06
CA3177952A1 (en) 2009-04-23
CA3006687C (en) 2024-01-09
CN104946591A (zh) 2015-09-30
JP2014168482A (ja) 2014-09-18
IL292561A (en) 2022-06-01
JP2022079484A (ja) 2022-05-26
PT2209888T (pt) 2020-01-17
JP2017136088A (ja) 2017-08-10
JP6137626B2 (ja) 2017-05-31

Similar Documents

Publication Publication Date Title
JP6137626B2 (ja) Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
US20240148784A1 (en) Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
AU2025205051A1 (en) Improved methods of producing RPE cells and compositions of RPE cells
HK40026818A (en) Improved methods of producing rpe cells and compositions of rpe cells
HK1149945A (en) Improved methods of producing rpe cells and compositions of rpe cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131002

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140725

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140818

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20141024

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150311